Atherosclerosis is the most common cause of renal artery stenosis (RAS) and exerts its effects through activation of the renin-angiotensin-aldosterone system (RAAS). Clinical manifestations of atherosclerotic renal artery stenosis (ARAS) include renovascular hypertension, cardiac destabilization syndromes, and ischemic nephropathy. Angiography is the gold standard for determining hemodynamically significant stenosis and stenosis >70% is deemed significant, while stenosis of 50%–70% requires further hemodynamic evaluation. Randomized controlled trials have failed to show benefit of renal artery stenting as a treatment modality for ARAS over optimal medical therapy; however, these trials are plagued by design and methodologic flaws and failed to enroll patients most likely to benefit from renal artery stenting. Here, we present a review of ARAS and consensus society guidelines for appropriateness of renal artery stenting, patient selection, procedural characteristics, and follow-up.
Clinical Impact
We present a brief case description of a patient who benefitted from stenting in ARAS and provide a comprehensive review of ARAS; its prevalence, pathophysiology, clinical manifestations, diagnosis and treatment. We review the evidence for and against stenting in ARAS as well as consensus guidelines for stenting. Our review is valuable as we argue that stenting in ARAS is underutilized and the randomized control data for stenting in those patients who may benefit most is lacking. Our review will provide an important perspective for clinicians faced with decisions of how to treat ARAS.
PlouinPFBaxL. Diagnosis and treatment of renal artery stenosis. Nat Rev Nephrol. 2010;6(3):151–159.
2.
GornikHLPersuAAdlamD, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24(2):164–189.
3.
RamanGAdamGPHalladayCW, et al. Comparative effectiveness of management strategies for renal artery stenosis: an updated systematic review. Ann Intern Med. 2016;165(9):635–649.
4.
CooperCJMurphyTPCutlipDE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2013;370(1):13–22.
5.
BaxLWoittiezAJKouwenbergHJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840–881, W150–W151.
6.
WheatleyKIvesNGrayR, et al; Angioplasty and Stenting for Renal Artery Lesions Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953–1962.
7.
ChrysochouCKalraPA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009;52(3):184–195.
8.
HansenKJEdwardsMSCravenTE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36(3):443–451.
9.
de MastQBeutlerJJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009;27(7):1333–1340.
10.
WeberBRDieterRS. Renal artery stenosis: epidemiology and treatment. Int J Nephrol Renovasc Dis. 2014;7:169–181.
11.
TextorSCLermanL. Renovascular hypertension and ischemic nephropathy. Am J Hypertens. 2010;23(11):1159–1169.
12.
MizunoYYoshimuraMYasueH, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103(1):72–77.
13.
FavaCMinuzPPatrignaniP, et al. Renal artery stenosis and accelerated atherosclerosis: which comes first?J Hypertens. 2006;24(9):1687–1696.
14.
PickeringTGHermanLDevereuxRB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet. 1988;2(8610):551–552.
15.
EdwardsMSCravenTEBurkeGLDeanRHHansenKJ. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch Intern Med. 2005;165(2):207–213.
16.
KurodaSNishidaNUzuT, et al. Prevalence of renal artery stenosis in autopsy patients with stroke. Stroke. 2000;31(1):61–65.
17.
CareyRMCalhounDABakrisGL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–e90.
18.
ChoncholMLinasS. Diagnosis and management of ischemic nephropathy. Clin J Am Soc Nephrol. 2006;1(2):172–181.
19.
PrinceMTafurJDWhiteCJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis?JACC Cardiovasc Interv. 2019;12(6):505–517.
20.
GranataAFioriniFAndrulliS, et al. Doppler ultrasound and renal artery stenosis: an overview. J Ultrasound. 2009;12(4):133–143.
21.
RadermacherJChavanABleckJ, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med. 2001;344(6):410–417.
22.
KrummeBHollenbeckM. Doppler sonography in renal artery stenosis—does the Resistive Index predict the success of intervention?Nephrology Dialysis Transplantation. 2006;22(3):692–696.
23.
García-CriadoAGilabertRNicolauC, et al. Value of Doppler sonography for predicting clinical outcome after renal artery revascularization in atherosclerotic renal artery stenosis. J Ultrasound Med. 2005;24(12):1641–1647.
24.
SchiedaNBlaichmanJICostaAF, et al. Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can J Kidney Health Dis. 2018;5:2054358118778573.
BaileySRBeckmanJADaoTD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology appropriate use criteria task force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol. 2019;73(2):214–237.
27.
PatelSMLiJParikhSA. Renal artery stenosis: optimal therapy and indications for revascularization. Curr Cardiol Rep. 2015;17(9):623.
28.
GrüntzigAKuhlmannUVetterWLütolfUMeierBSiegenthalerW. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. Lancet. 1978;1(8068):801–802.
29.
RitchieJGreenDChrysochouC, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis. 2014;63(2):186–197.
30.
GrayBHOlinJWChildsMB, et al. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 2002;7(4):275–279.
31.
VassalloDRitchieJGreenDChrysochouCKalraPA. The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features. Nephrol Dial Transplant. 2018;33(3):497–506.
32.
ReinhardMSchousboeKAndersenUB, et al. Renal artery stenting in consecutive high-risk patients with atherosclerotic renovascular disease: a prospective 2-center cohort study. J Am Heart Assoc. 2022;11(7):e024421.
33.
ThatipelliMRSabaterEABjarnasonH, et al. CT angiography of renal artery anatomy for evaluating embolic protection devices. J Vasc Interv Radiol. 2007;18(7):842–846.
34.
ZähringerMSapovalMPattynamaPM, et al. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007;14(4):460–468.
35.
MisraSThatipelliMRHowePW, et al. Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenoses 4 mm in diameter or smaller. J Vasc Interv Radiol. 2008;19(6):833–839.
36.
BradaricCEserKPreussS, et al. Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease. Eurointervention. 2017;13(2):e248–e255.
